Planned Phase 2 Trial of ANVS401, Targeting Toxic Proteins, Moving Forward
A planned Phase 2 clinical trial evaluating ANVS401, Annovis Bio‘s lead investigational therapy for people in the early stages of Alzheimer’s and Parkinson’s disease, has received approval from a central institutional review board (IRB). An IRB is an administrative body responsible for protecting the rights and welfare of human research…